Small biotechs with big drug ambitions threaten to upend the traditional drug launch playbook

Amber Tong

Of the countless decisions Vlad Coric had to make as Biohaven’s CEO over the past seven years, there was one that felt particularly nerve-wracking: Instead …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Small biotechs with big drug ambitions threaten to upend the traditional drug launch playbook

Amber Tong

Sign up to read this article for free.

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Athira gives up on lead Alzheimer’s drug, switches tack to ALS

Nkarta drops another cancer program as it leans into autoimmune disease

Senior AstraZeneca exec detained in China amid wider investigation

Pfizer to invest $1B in China over next five years — reports

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

Amber Tong

Sign up to read this article for free.

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Athi­ra gives up on lead Alzheimer’s drug, switch­es tack to ALS

Nkar­ta drops an­oth­er can­cer pro­gram as it leans in­to au­toim­mune dis­ease

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Small biotechs with big drug ambitions threaten to upend the traditional drug launch playbook

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Athira gives up on lead Alzheimer’s drug, switches tack to ALS

Nkarta drops another cancer program as it leans into autoimmune disease

Senior AstraZeneca exec detained in China amid wider investigation

Pfizer to invest $1B in China over next five years — reports

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks